RxDoctor Payments Data

Mamle Anim, MD

Internal Medicine · Dayton, OHNPI 1790741536

Payments from drug & device makers

$36,813in general payments, 2019–2025

Across 56 payments — averaging $657.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Global Blood Therapeutics, Inc.$19K
  • Novartis$16K
  • Pfizer$1K
  • Novo Nordisk$125
  • Gilead$64
  • Alkermes, Inc.$13

What the payments were for

  • Consulting fees$5,33915%
  • Speaking & faculty fees$25,93970%
  • Travel & lodging$4,04511%
  • Food & beverage$1,4774%
  • Education$130%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Global Blood Therapeutics, Inc.23$19,181
Novartis25$16,057
Pfizer2$1,374
Novo Nordisk1$125
Gilead4$64
Alkermes, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,813 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$225
Medicare patients
11
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxbrytaVoxelotor24$291,423
OxycontinOxycodone Hcl37$56,581
OzempicSemaglutide44$46,119
Deferasirox24$32,093
ShingrixVaricella-Zoster Ge/As01b/Pf133$25,515
JardianceEmpagliflozin15$24,000
TrulicityDulaglutide17$20,245
EliquisApixaban17$11,483
Bydureon BciseExenatide Microspheres12$9,439
SymbicortBudesonide/Formoterol Fumarate17$3,670
Naltrexone Hcl13$3,542
Morphine Sulfate ErMorphine Sulfate30$1,621
Oxycodone Hcl46$1,310
Albuterol Sulfate HfaAlbuterol Sulfate36$1,285
Hydroxyurea12$988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Global Blood Therapeutics, Inc.Oxbryta$19,181$291,42324 claims
Novo NordiskOzempic$125$46,11944 claims
PfizerEliquis$1,374$11,48317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →